IP Library Granted Patent US 7,629,311
Granted Patent B2
US 7,629,311 · App. 11/601,799 · Granted Dec 8, 2009

Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers

Assignee: Edward Lewis Tobinick
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,629,311
App. No.
11/601,799
Granted
Dec 8, 2009
Kind
B2
Abstract

A method for delivering a biologic to a human with Alzheimer's-related dementia, comprising administering the biologic parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human's head below the horizontal. The method further includes delivering a TNF antagonist to the brain of a human for treating mild cognitive impairment, Alzheimer's related dementia, or vascular dementia, comprising administering the TNF antagonist golimumab parenterally into the perispinal space of the human without direct intrathecal injection, and thereafter positioning the human in a Trendelenburg position, for delivery of the golimumab to the brain via the human's vertebral venous system.

Claims (7)

1. A method for delivering a biologic to a human with Alzheimer's-related dementia, comprising the steps of administering said biologic parenterally into the perispinal space of said human without direct intrathecal injection, and positioning said human in a Trendelenburg position.

2. The method of claim 1 , wherein said biologic is etanercept.

3. The method of claim 1 , wherein said biologic is golimumab.

4. The method of claim 1 , wherein said biologic is immune globulin.

5. The method of claim 1 , wherein said biologic is bapineuzumab.

6. The method of claim 1 , wherein said administered biologic reaches the brain by retrograde blood flow, and thereby bypasses the blood-brain barrier to reach the brain.

7. The method of claim 1 , wherein the biologic is certolizumab pegol.

Assignments (3)
ADDRESS CHANGE Recorded Oct 4, 2017
From: TACT IP, LLC
To: TACT IP, LLC
Reel/Frame 044127/0229 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2010
From: TOBINICK, EDWARD L., DR.
To: TACT IP, LLC
Reel/Frame 025126/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2006
From: TOBINICK, EDWARD LEWIS
To: EDWARD LEWIS TOBINICK, M.D.
Reel/Frame 018619/0730 →
Continuity (14)
Continuation In Part 1101604700 · Dec 18, 2004
Continuation In Part 1026974500 · Oct 9, 2002
Continuation In Part 1023609700 · Sep 6, 2002
Continuation In Part 0984184400 · Apr 25, 2001
Continuation In Part 0982697600 · Apr 5, 2001
Continuation In Part 0956365100 · May 2, 2000
Continuation In Part 0947664300 · Dec 31, 1999
Continuation In Part 0927507000 · Mar 23, 1999
Continuation In Part 0925638800 · Feb 24, 1999
Provisional Application 6073833100 · Nov 18, 2005
Provisional Application 6076023600 · Jan 18, 2006
Provisional Application 6066274400 · Mar 16, 2005
Provisional Application 6058573500 · Jul 6, 2004
Related Publication 20070196375A1 · Aug 23, 2007